Phase V Technologies
Company
Phase V Technologies develops one asset, in phase 2 (Bezisterim in Alzheimer's disease). Mostly small molecule acting on NF-κB signalling, epigenetic regulation of gene expression and inflammation.
- 1
- Asset
- Furthest stage
- Phase 2
- 0
- Trials
- 0
- Signals
Pipeline
1Oral anti-inflammatory insulin-sensitizing neurosteroid agent modulating NF-kB and DNA promoter methylation
Phase 2, Small molecule, NF-κB signalling, Epigenetic regulation of gene expression, Alzheimer's disease, Parkinson's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Signals3
- Similar companies6
Papers
ADA Scientific Sessions 2026 abstract, 5 Jun 2026